Cargando…

Venetoclax and Azacitidine Treatment in Relapsed Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation: A Cohort Study in the Real-World Setting of a Tertiary Center

Detalles Bibliográficos
Autores principales:	Göker, Hakan, Çınar, Olgu Erkin, Demiroğlu, Haluk, Malkan, Ümit Yavuz, Aladağ Karakulak, Elifcan, Büyükaşık, Yahya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2023
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476247/ https://www.ncbi.nlm.nih.gov/pubmed/37314288 http://dx.doi.org/10.4274/tjh.galenos.2023.2023.0089

Ejemplares similares

Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
por: ALADAĞ, Elifcan, et al.
Publicado: (2021)

Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
por: Malkan, Umit Yavuz, et al.
Publicado: (2021)

The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients
por: KARATAŞ, Ayşe, et al.
Publicado: (2021)

Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study
por: Aladağ, Elifcan, et al.
Publicado: (2021)

A single-center experience of haploidentical stem cell transplantation in hematological malignancies
por: MALKAN, Ümit Yavuz, et al.
Publicado: (2022)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation
por: KARATAŞ, Ayşe, et al.
Publicado: (2022)

Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study
por: Çiftçiler, Rafiye, et al.
Publicado: (2019)

CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation
por: ALADAĞ, Elifcan, et al.
Publicado: (2020)

Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease
por: Gunes, Gursel, et al.
Publicado: (2015)

Central nervous system involvement in patients with acute myeloid leukemia
por: YAŞAR, Hatime Arzu, et al.
Publicado: (2021)

All-trans Retinoic Acid–Induced Isolated Myocarditis: A Case Report and Review of the Literature
por: Karakulak, Ugur Nadir, et al.
Publicado: (2020)

The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia
por: Çiftçiler, Rafiye, et al.
Publicado: (2020)

Prophylactic Central Nervous System Irradiation Is Not Indispensable in Adult Patients with Acute Lymphoblastic Leukemia: A Multicenter Retrospective Cohort Study
por: Çınar, Olgu Erkin, et al.
Publicado: (2022)

Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874
por: Çınar, Olgu Erkin, et al.
Publicado: (2022)

Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis
por: Çiftçiler, Rafiye, et al.
Publicado: (2020)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

The effects of blood group types on the risk of COVID-19 infection and its clinical outcome
por: GÖKER, Hakan, et al.
Publicado: (2020)

Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency
por: ALADAĞ, Elifcan, et al.
Publicado: (2019)

Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission
por: Aydın, Mürüvvet Seda, et al.
Publicado: (2017)

Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse
por: Malkan, Umit Yavuz, et al.
Publicado: (2015)

Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case
por: Malkan, Umit Y., et al.
Publicado: (2018)

Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma
por: Demiroğlu, Haluk, et al.
Publicado: (2021)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
por: Garciaz, Sylvain, et al.
Publicado: (2022)

Enterotoxins A and B produced by Staphylococcus aureus increase cell proliferation, invasion and cytarabine resistance in acute myeloid leukemia cell lines
por: Turk, Seyhan, et al.
Publicado: (2023)

The Prognosis of Adult Burkitt’s Cell Leukemia in Real-Life Clinical Practice
por: Malkan, Ümit Yavuz, et al.
Publicado: (2016)

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma
por: Karataş, Ayşe, et al.
Publicado: (2020)

Acute Graft-Versus-Host Disease: A Brief Review
por: Aladağ, Elifcan, et al.
Publicado: (2020)

Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation
por: Zhao, Peng, et al.
Publicado: (2021)

Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis
por: Çınar, Olgu Erkin, et al.
Publicado: (2020)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax
por: Niswander, Lisa M., et al.
Publicado: (2023)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Downregulation of Stearoyl-CoA Desaturase 1 (SCD-1) Promotes Resistance to Imatinib in Chronic Myeloid Leukemia
por: Altinok Gunes, Buket, et al.
Publicado: (2023)

Determination of etiology in patients admitted due to isolated leukopenia
por: Mart, Gulay, et al.
Publicado: (2022)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Xia, Leiming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m57gr86chok5v4rddb3cpqne6l